For unresectable/metastatic cholangiocarcinoma, would you continue gemcitabine/cisplatin beyond 24 weeks if the patient continues to have a response to therapy?

I frequently continue beyond the 24 weeks used in the ABC-02 trial. Despite scarcity of good quality evidence, some form of maintenance chemotherapy is increasingly being used in advanced non-colorectal GI cancers such as biliary, pancreatic and esophagogastric cancers. More prolonged therapy has al...